Eiger BioPharmaceuticals (NASDAQ:EIGR) Stock Price Passes Below 200-Day Moving Average of $6.86

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGRGet Rating)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.86 and traded as low as $4.10. Eiger BioPharmaceuticals shares last traded at $4.11, with a volume of 173,324 shares.

Wall Street Analysts Forecast Growth

EIGR has been the subject of several recent analyst reports. BTIG Research reduced their price objective on shares of Eiger BioPharmaceuticals from $57.00 to $48.00 and set a “buy” rating for the company in a research report on Wednesday, September 7th. StockNews.com cut shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 4th.

Eiger BioPharmaceuticals Stock Down 1.4 %

The business’s fifty day moving average price is $5.63 and its 200 day moving average price is $6.86. The firm has a market capitalization of $181.13 million, a price-to-earnings ratio of -1.71 and a beta of 1.44. The company has a current ratio of 5.45, a quick ratio of 5.34 and a debt-to-equity ratio of 0.50.

Hedge Funds Weigh In On Eiger BioPharmaceuticals

A number of institutional investors have recently modified their holdings of EIGR. 683 Capital Management LLC increased its holdings in shares of Eiger BioPharmaceuticals by 12.0% in the 3rd quarter. 683 Capital Management LLC now owns 4,329,751 shares of the biotechnology company’s stock valued at $32,603,000 after acquiring an additional 464,751 shares during the period. State Street Corp increased its stake in Eiger BioPharmaceuticals by 26.7% in the 2nd quarter. State Street Corp now owns 702,350 shares of the biotechnology company’s stock valued at $4,425,000 after buying an additional 148,035 shares during the period. Prudential Financial Inc. increased its stake in Eiger BioPharmaceuticals by 222.4% in the 3rd quarter. Prudential Financial Inc. now owns 197,795 shares of the biotechnology company’s stock valued at $1,489,000 after buying an additional 136,440 shares during the period. EAM Investors LLC acquired a new position in Eiger BioPharmaceuticals in the 1st quarter valued at $1,052,000. Finally, Dimensional Fund Advisors LP increased its stake in Eiger BioPharmaceuticals by 23.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 662,369 shares of the biotechnology company’s stock valued at $4,988,000 after buying an additional 124,754 shares during the period. 67.87% of the stock is owned by institutional investors and hedge funds.

Eiger BioPharmaceuticals Company Profile

(Get Rating)

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.

See Also

Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.